Trial Profile
A Pilot Study of Preoperative Nivolumab in High-Risk Non-Metastatic and Metastatic Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Immunotherapies; Ipilimumab
- Indications Acute myeloid leukaemia; Carcinoma; Renal cell carcinoma
- Focus Adverse reactions
- 01 Jun 2022 Results assessing safety and feasibility of neoadjuvant nivolumab in patients undergoing nephrectomy for localized renal cell carcinoma, published in the European Urology.
- 13 Sep 2021 Results (n=21) retrospectively assesseing a separate cohort patients with metastatic Renal Cell Carcinoma who received preoperative ICI off protocol, presented at the 116th Annual Meeting of the American Urological Association
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium